Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 9th World Drug Delivery Summit New Orleans, Louisiana, USA.

Day 1 :

OMICS International Drug Delivery 2016 International Conference Keynote Speaker Hiroshi Maeda  photo

Hiroshi Maeda is a world renowned expert in macromolecular therapeutics. He created the world first polymeric-conjugate drug, SMANCS, approved for treatment of hepatoma in Japan. Consequently, he discovered the concept of EPR effect of macromolecular-drugs, ubiquitous mechanism for solid tumor selective targeting of polymeric drugs. He received MS, University of California, Devis, Fulbright student, Ph.D., M.D., Tohoku University. He published more than 450 papers in reputed journals. He was awarded Lifetime-Achievement-Award at Royal-Pharmaceutical-Society, Princess-Takamatsu-Award in Cancer Research, Tomizo-Yoshida-Award, highest award of Japan-Cancer-Assoc., and also selected as most cited influential scientist in pharmacology by Thomson Reuters 2014, and H-index of 89.


Tumor selective targeting using macromolecular drugs was started when poly (styrene-co-maleic acid) was conjugated to protein (NCS) forming SMANCS in 1979. We then investigated most biocompatible plasma proteins, and synthetic polymers of various sizes for tumor uptake: We found >40KDa-polymers were selectively taken up into the tumor: This tumor selective uptake phenomenon was coined EPR (enhanced permeability and retention) effect of solid tumors in 1986: The EPR reflects architectural defect of tumor vasculature and excessive production of many vascular effectors as in inflammation, eg. bradykinin, nitric oxide, etc. EPR effect was also demonstrated in metastatic cancers recently. Heterogeneity of EPR in many tumors may be caused by tumor thrombus or suppressed blood-flow. We showed several vascular mediators can augment EPR effect such as NO releasing agents and ACE-inhibitor (eg. enalapril) which potentiates bradykinin. They not only restore vascular flow but also augment EPR effect for macromolecular delivery 2-3 folds. EPR effect will be similarly applied for delivery of fluorescent nanoprobes; it becomes beneficial for novel imaging and photodynamic therapy. Iv injection of fluorescent Zn-protoporphyrin nanoprobes in rat with autochthonous breast cancer, followed by 2-3 times photo-irradiation by endoscope, resulted in complete tumor regression. This advantage is also great value for in vivo tumor detection using fluorescent endoscope. rnThe EPR effect is yet the first step for selective tumor delivery. However, drug translocation to tumor cell-membrane and intracellular target are remaining issues. We will show our state-of-the-art-for these points, utilizing tissue-pH of tumor (acidic), and membrane transporters upregulated in tumors. 

Keynote Forum

Damon Smith

Altus Formulation Inc., Canada

Keynote: ACETAFLEX: A Novel Breakable 12hr Extended Release Acetaminophen Formulation

Time : 10:15-10:45

OMICS International Drug Delivery 2016 International Conference Keynote Speaker Damon Smith photo

Damon Smith is the founder and CEO of Altus Formulation, a Montreal based drug development company. Damon holds a Ph.D in biological chemistry and has over 27 years of experience in start-up to commercialization companies in the UK, Australia and N.America.


Acetaminophen (Paracetamol or APAP) is a low potency analgesic used to treat a range of pain indications. Thus, APAP may be infused intravenously for postoperative pain and combined with codeine or tramadol to treat mild to moderate pain. Best known of APAP’s uses however is the treatment of mild pain where it is available over the counter as immediate release (IR) or extended release (ER) tablets providing up to 8 hours of relief. Despite the long history of this medication APAP, unlike other products in this market, has never been available as a 12hr duration ER tablet. rnrnHere we report the development of a novel breakable extended release formulation of APAP developed using FLEXITABTM technology to address this unmet need. FLEXITAB 12hr controlled release tablets (ACETAFLEXTM) are 750mg bilayer matrix tablets designed to provide both early onset and sustained analgesia. In a placebo controlled 403 patient Ph II human proof-of-concept study to assess the safety and efficacy of the tablets in a postoperative dental pain model, pain intensity difference (PID) and pain relief (PAR) scores were statistically greater for ACETAFLEX compared to placebo beginning at 15 minutes and continuing through 12hrs supporting that the analgesic effect of the tablets was maintained for this period. In addition the study medication was well tolerated with no serious adverse events being reported; one placebo-treated subject withdrew from the study due to an adverse event (emesis). Breaking of the tablets resulted in little to no change in their drug release rate which was also maintained in the presense of ethanol (40% wt/wt) whether intact or divided along the score.

Keynote Forum

Istvan Toth

The University of Queensland, Australia

Keynote: Self-adjuvanting vaccine design to control fertility and prevent infectious diseases

Time : 09:25-09:50

OMICS International Drug Delivery 2016 International Conference Keynote Speaker Istvan Toth photo

Istvan Toth, PhD, DSc is a Chemical Engineer, ARC Australia Professorial Fellow, Chair in Biological Chemistry and Professor of Pharmacy at the University of Queensland. His major research interest these days is drug, vaccine and gene delivery. He is active in research commercialization as one of the key founders of Alchemia (ASX listed), Implicit Bioscience, Neurotide and TetraQ. He has more than 300 peer-reviewed publications and 43 patents. He is the Editor-in-Chief of Current Drug Delivery, and Drug Delivery Letters. He is a Fellow of the Royal Australian Chemical Institute (FRACI) and the Queensland Academy of Science and Art (FQA).


Immunocastration using gonadotropin-releasing hormone (GnRH)-based vaccines has been investigated in rams to control fertility. A GnRH-lipopeptide vaccine (GnRH-LP) including two copies of GnRH, lipids (2-amino-D, L-hexadecanoic acid), and a ram specific T helper epitope, was designed and synthesised. Rams were vaccinated with or without additional adjuvant. In both groups anti-GnRH antibodies were generated. Additionally rams showed a marked decrease in testicular size, providing the basis for an effective immunocastration. The attachment of synthetic lipids to peptide antigens has been shown to effectively increase the immune response to poorly immunogenic peptide antigens. Furthermore, dendritic polypeptides, polymeric nanoparticles, and carbohydrates provide multiple attachment points for peptides. The conjugation of multiple copies of a single peptide to a carrier has been demonstrated to produce higher antibody responses than a single peptide epitope. Therefore, the conjugation of the lipid core peptide (LCP) system (adjuvant) with sugar units (carrier) represents one of the most important strategies currently under investigation for drug delivery. The LCP-system has been demonstrated to adjuvant peptide epitopes from several group A streptococcal (GAS) strains. GAS is one of the most common human pathogens, and causes a wide range of infections, including: acute rheumatic fever, rheumatic heart disease, and acute glomerulonephritis. Opsonic antibodies directed against the surface M protein, a major virulence factor of GAS, mediate protection against GAS infection.